Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.40 |
| ▸ | CTSD | P07339 | 2/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rolgamidine SCHEMBL10912462 | 1.00 | BACE1 (0.40) | BACE1CTSDSLC9A1BACE2ADRA2A | |
| Rolgamidine SCHEMBL10909853 | 1.00 | BACE1 (0.40) | BACE1CTSDSLC9A1BACE2ADRA2A | |
| Rolgamidine SCHEMBL10911887 | 0.95 | BACE1 (0.37) | BACE1CTSDSLC9A1BACE2ADRA2A | |
| SCHEMBL11541960 | 0.77 | BACE1 (0.37) | BACE1CTSDSLC9A1BACE2 | |
| SCHEMBL11541956 | 0.77 | BACE1 (0.37) | BACE1CTSDSLC9A1BACE2 | |
| SCHEMBL11541952 | 0.77 | BACE1 (0.37) | BACE1CTSDSLC9A1BACE2 | |
| SCHEMBL11062551 | 0.65 | BACE1 (0.60) | BACE1CTSDSLC9A1BACE2ADRA2A | |
| SCHEMBL11536395 | 0.64 | — | — | |
| SCHEMBL11536407 | 0.64 | — | — | |
| SCHEMBL1070818 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0040947-B1 | USE OF GUANIDINES FOR MANUFACTURING ANTIDIARRHOEAL MEDICAMENTS AND ANTIDIARRHOEAL COMPOSITIONS CONTAINING THESE GUANIDINES | JOHN WYETH & BROTHER LIMITED (GB) | 1986-12-03 | — | — | EP | claimed |
| US-4443467-A | N-DIAMINOMETHYLENE-(2,5-DIHYDRO-1H-PYRROL-1-YL)ACETAMIDES | JOHN WYETH & BROTHER, LIMITED (GB) | 1984-04-17 | — | — | US | claimed |
| EP-0040947-A1 | Use of guanidines for manufacturing antidiarrhoeal medicaments and antidiarrhoeal compositions containing these guanidines | JOHN WYETH & BROTHER LIMITED (GB) | 1981-12-02 | — | — | EP | claimed |
| US-4140793-A | HYPOGLYCEMIC AGENTS, ANTIULCER AGENTS | JOHN WYETH & BROTHER, LTD. (GB) | 1979-02-20 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-4443467-A | N-DIAMINOMETHYLENE-(2,5-DIHYDRO-1H-PYRROL-1-YL)ACETAMIDES | JOHN WYETH & BROTHER, LIMITED (GB) | 1984-04-17 | — | — | US | disclosed |
| EP-0040947-A1 | Use of guanidines for manufacturing antidiarrhoeal medicaments and antidiarrhoeal compositions containing these guanidines | JOHN WYETH & BROTHER LIMITED (GB) | 1981-12-02 | — | — | EP | disclosed |
| US-4140793-A | HYPOGLYCEMIC AGENTS, ANTIULCER AGENTS | JOHN WYETH & BROTHER, LTD. (GB) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | BACE1 141/4885CTSD 240/4885SLC9A1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.